Search

Your search keyword '"Van Assche G"' showing total 32 results
Start Over Author "Van Assche G" Publisher wiley
32 results on '"Van Assche G"'

1. An expert consensus to standardise definitions, diagnosis and treatment targets for anti‐fibrotic stricture therapies in Crohn's disease

Author

Rieder, F., primary, Bettenworth, D., additional, Ma, C., additional, Parker, C. E., additional, Williamson, L. A., additional, Nelson, S. A., additional, van Assche, G., additional, Di Sabatino, A., additional, Bouhnik, Y., additional, Stidham, R. W., additional, Dignass, A., additional, Rogler, G., additional, Taylor, S. A., additional, Stoker, J., additional, Rimola, J., additional, Baker, M. E., additional, Fletcher, J. G., additional, Panes, J., additional, Sandborn, W. J., additional, Feagan, B. G., additional, and Jairath, V., additional

Published
2018
Full Text
View/download PDF

4. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

Author

Colombel, J.-F., primary, Sandborn, W. J., additional, Reinisch, W., additional, Peyrin-Biroulet, L., additional, Panaccione, R., additional, Rutgeerts, P., additional, Hanauer, S. B., additional, Ghosh, S., additional, Van Assche, G., additional, Robinson, A. M., additional, Lau, W., additional, Maa, J.-F., additional, Huang, B., additional, Pappalardo, B., additional, and Read, H., additional

Published
2017
Full Text
View/download PDF

12. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease

Author

Khanna, R., primary, Sattin, B. D., additional, Afif, W., additional, Benchimol, E. I., additional, Bernard, E.-J., additional, Bitton, A., additional, Bressler, B., additional, Fedorak, R. N., additional, Ghosh, S., additional, Greenberg, G. R., additional, Marshall, J. K., additional, Panaccione, R., additional, Seidman, E. G., additional, Silverberg, M. S., additional, Steinhart, A. H., additional, Sy, R., additional, Van Assche, G., additional, Walters, T. D., additional, Sandborn, W. J., additional, and Feagan, B. G., additional

Published
2013
Full Text
View/download PDF

13. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

Author

Sandborn, W. J., primary, Colombel, J.-F., additional, D'Haens, G., additional, Van Assche, G., additional, Wolf, D., additional, Kron, M., additional, Lazar, A., additional, Robinson, A. M., additional, Yang, M., additional, Chao, J. D., additional, and Thakkar, R., additional

Published
2012
Full Text
View/download PDF

18. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies

Author

ALLEZ, M., primary, VERMEIRE, S., additional, MOZZICONACCI, N., additional, MICHETTI, P., additional, LAHARIE, D., additional, LOUIS, E., additional, BIGARD, M.-A., additional, HÉBUTERNE, X., additional, TRETON, X., additional, KOHN, A., additional, MARTEAU, P., additional, CORTOT, A., additional, NICHITA, C., additional, VAN ASSCHE, G., additional, RUTGEERTS, P., additional, LÉMANN, M., additional, and COLOMBEL, J.-F., additional

Published
2010
Full Text
View/download PDF

30. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.

Author

Verstockt B, Claeys C, De Hertogh G, Van Assche G, Wolthuis A, D'Hoore A, Vermeire S, and Ferrante M

Subjects
Adult, Anti-Bacterial Agents therapeutic use, Biological Products therapeutic use, Chronic Disease, Colitis, Ulcerative surgery, Female, Humans, Male, Middle Aged, Proctocolectomy, Restorative, Retrospective Studies, Treatment Failure, Treatment Outcome, Adalimumab therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Gastrointestinal Agents therapeutic use, Infliximab therapeutic use, Pouchitis drug therapy, Tumor Necrosis Factor Inhibitors therapeutic use
Abstract

Background: In limited retrospective series, infliximab, adalimumab and vedolizumab have demonstrated efficacy in chronic antibiotic-refractory pouchitis. Here, we report single-centre data of all biological therapies in refractory pouchitis., Methods: We retrospectively assessed all records from patients with ulcerative colitis and ileal pouch -anal anastomosis who received infliximab, adalimumab or vedolizumab for pouchitis. Clinically relevant remission, defined as a modified Pouchitis Disease Activity Index <5 and a reduction of modified Pouchitis Disease Activity Index ≥2 points from baseline, was assessed at week 14., Results: Thirty-three unique patients were identified. Prior to colectomy, patients had been exposed to cyclosporine ( n  = 14), infliximab ( n  = 12), adalimumab ( n  = 3), and/or vedolizumab ( n  = 3). All developed chronic antibiotic-refractory pouchitis, for which they received infliximab ( n  = 23), adalimumab ( n  = 13) or vedolizumab ( n  = 15). Clinically relevant remission was observed in 43.5% of patients in the infliximab group, and in 38.5% and 60.0% in the adalimumab and vedolizumab group, respectively. In the long-term, significantly more patients continued vedolizumab compared to anti-tumour necrosis factor (anti-TNF) therapy (hazard ratio 3.0, p  = 0.04). Adverse events (mainly infusion reactions) explained 40.7% of the patients discontinuing anti-TNF therapy, whereas discontinuation of vedolizumab was only related to insufficient efficacy. Four patients eventually required a permanent ileostomy., Conclusion: In this case series of chronic antibiotic-refractory pouchitis, biological therapy was effective in the majority of patients and only a minority eventually required a permanent ileostomy. The use of anti-TNF agents was hampered by a high rate of adverse events, partly related to immunogenicity as some patients had been exposed to anti-TNF prior to colectomy. Vedolizumab was also efficacious and may provide a safe alternative in these chronic antibiotic-refractory pouchitis patients., (© Author(s) 2019.)

Published
2019
Full Text
View/download PDF

31. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study.

Author

Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, and Ferrante M

Abstract

Background: Histological remission has been proposed as a new treatment goal in patients with ulcerative colitis (UC) although no universal definition for microscopic activity exists., Aim: We evaluated the accuracy of histological activity to predict clinical relapse in UC patients with both clinical and endoscopic remission., Methods: Asymptomatic UC patients in endoscopic remission (Mayo endoscopic sub-score 0 or 1) undergoing surveillance colonoscopy in two referral hospitals were prospectively recruited. All colonic biopsies were analyzed according to the Geboes' score (GS) and the presence of basal plasmacytosis (BP)., Results: Ninety-six patients were included (38% women, median (interquartile range) age 50.0 (39.0-58.5) years, median disease duration 12.0 (6.5-19.5) years). Histological activity defined as GS ≥ 2B.1, GS ≥ 3.1, or BP was present in, respectively, 26%, 23% and 12%. Within 12 months from index endoscopy, 23% of the patients presented with clinical relapse. In multivariate analysis, active histological disease was the only risk factor predicting clinical relapse (odds ratio (95% confidence interval) 4.29 (1.55-11.87); p  = 0.005 for GS ≥ 2B.1 and 4.31 (1.52-12.21); p  = 0.006 for GS ≥ 3.1)., Conclusions: In patients with UC in clinical and endoscopic remission, histological activity is an independent risk factor for clinical relapse. Further prospective studies need to clarify whether treatment optimization is justified in this context.

Published
2018
Full Text
View/download PDF

32. Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology.

Author

Noben M, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, and Ferrante M

Abstract

Determining the exact pathogenesis of chronic gastrointestinal diseases remains difficult due to the complex in vivo environment. In this review we give an overview of the available epithelial cell culture systems developed to investigate pathophysiology of gastrointestinal diseases. Traditionally used two-dimensional (2D) immortalised (tumour) cell lines survive long-term, but are not genetically stable nor represent any human in particular. In contrast, primary cultures are patient unique, but short-lived. Three-dimensional (3D) organoid cultures resemble the crypt-villus domain and contain all cell lineages, are long-lived and genetically stable. Unfortunately, manipulation of the 3D organoid system is more challenging. Combining the 3D and 2D technologies may overcome limitations and offer the formation of monolayers on permeable membranes or flow-chambers. Determining the right model to use will depend on the pathology of interest and the focus of the research, defining which cell types need to be included in the model.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results